CN118076591A - 新的曲美他嗪盐 - Google Patents
新的曲美他嗪盐 Download PDFInfo
- Publication number
- CN118076591A CN118076591A CN202280068113.8A CN202280068113A CN118076591A CN 118076591 A CN118076591 A CN 118076591A CN 202280068113 A CN202280068113 A CN 202280068113A CN 118076591 A CN118076591 A CN 118076591A
- Authority
- CN
- China
- Prior art keywords
- trimetazidine
- acid
- salt
- pharmaceutical composition
- hemi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21306465.2 | 2021-10-20 | ||
| EP21306465 | 2021-10-20 | ||
| PCT/EP2022/079054 WO2023066971A1 (en) | 2021-10-20 | 2022-10-19 | Novel trimetazidine salts |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118076591A true CN118076591A (zh) | 2024-05-24 |
Family
ID=78592764
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202280068113.8A Pending CN118076591A (zh) | 2021-10-20 | 2022-10-19 | 新的曲美他嗪盐 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20250250245A1 (enExample) |
| EP (1) | EP4419510B1 (enExample) |
| JP (1) | JP2024539090A (enExample) |
| KR (1) | KR20240093576A (enExample) |
| CN (1) | CN118076591A (enExample) |
| AR (1) | AR127403A1 (enExample) |
| AU (1) | AU2022369026A1 (enExample) |
| CR (1) | CR20240157A (enExample) |
| DK (1) | DK4419510T3 (enExample) |
| ES (1) | ES3057370T3 (enExample) |
| HR (1) | HRP20251413T1 (enExample) |
| IL (1) | IL311916A (enExample) |
| LT (1) | LT4419510T (enExample) |
| MA (1) | MA66951B1 (enExample) |
| MX (1) | MX2024004714A (enExample) |
| PL (1) | PL4419510T3 (enExample) |
| PT (1) | PT4419510T (enExample) |
| RS (1) | RS67449B1 (enExample) |
| SI (1) | SI4419510T1 (enExample) |
| WO (1) | WO2023066971A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025106477A1 (en) * | 2023-11-14 | 2025-05-22 | Samsara Therapeutics Inc. | Novel autophagy inducing compounds and uses thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104138376A (zh) * | 2013-05-06 | 2014-11-12 | 常州高新技术产业开发区三维工业技术研究所有限公司 | 一种提高缺氧耐受力的缓释剂 |
| FR3027803B1 (fr) | 2014-11-05 | 2018-02-09 | Les Laboratoires Servier | Composition pharmaceutique comprenant un betabloquant et un inhibiteur de l'enzyme de conversion |
| CN105287564A (zh) * | 2015-09-06 | 2016-02-03 | 余祖江 | 一种防治肝病的西药复合物及其用途 |
| CN110183398B (zh) | 2019-05-14 | 2021-06-29 | 中南民族大学 | 一种曲美他嗪草酸盐及其制备方法和应用 |
| CN110105307B (zh) | 2019-05-14 | 2021-06-01 | 中南民族大学 | 一种曲美他嗪草酸盐及其制备方法和应用 |
| CN110054599B (zh) * | 2019-05-14 | 2021-05-07 | 中南民族大学 | 一种曲美他嗪草酸盐及其制备方法和应用 |
| CN112043691A (zh) * | 2019-06-06 | 2020-12-08 | 常州高新技术产业开发区三维工业技术研究所有限公司 | 一种药物组合物及其用途 |
-
2022
- 2022-10-19 RS RS20251183A patent/RS67449B1/sr unknown
- 2022-10-19 MX MX2024004714A patent/MX2024004714A/es unknown
- 2022-10-19 CR CR20240157A patent/CR20240157A/es unknown
- 2022-10-19 LT LTEPPCT/EP2022/079054T patent/LT4419510T/lt unknown
- 2022-10-19 US US18/702,363 patent/US20250250245A1/en active Pending
- 2022-10-19 AR ARP220102840A patent/AR127403A1/es unknown
- 2022-10-19 EP EP22808665.8A patent/EP4419510B1/en active Active
- 2022-10-19 IL IL311916A patent/IL311916A/en unknown
- 2022-10-19 PL PL22808665.8T patent/PL4419510T3/pl unknown
- 2022-10-19 AU AU2022369026A patent/AU2022369026A1/en active Pending
- 2022-10-19 ES ES22808665T patent/ES3057370T3/es active Active
- 2022-10-19 SI SI202230206T patent/SI4419510T1/sl unknown
- 2022-10-19 PT PT228086658T patent/PT4419510T/pt unknown
- 2022-10-19 DK DK22808665.8T patent/DK4419510T3/da active
- 2022-10-19 HR HRP20251413TT patent/HRP20251413T1/hr unknown
- 2022-10-19 WO PCT/EP2022/079054 patent/WO2023066971A1/en not_active Ceased
- 2022-10-19 MA MA66951A patent/MA66951B1/fr unknown
- 2022-10-19 JP JP2024523404A patent/JP2024539090A/ja active Pending
- 2022-10-19 CN CN202280068113.8A patent/CN118076591A/zh active Pending
- 2022-10-19 KR KR1020247015968A patent/KR20240093576A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL311916A (en) | 2024-06-01 |
| CR20240157A (es) | 2024-05-22 |
| EP4419510B1 (en) | 2025-10-08 |
| ES3057370T3 (en) | 2026-03-02 |
| WO2023066971A1 (en) | 2023-04-27 |
| JP2024539090A (ja) | 2024-10-28 |
| LT4419510T (lt) | 2025-12-29 |
| CA3234743A1 (en) | 2023-04-27 |
| US20250250245A1 (en) | 2025-08-07 |
| RS67449B1 (sr) | 2025-12-31 |
| AR127403A1 (es) | 2024-01-17 |
| KR20240093576A (ko) | 2024-06-24 |
| EP4419510A1 (en) | 2024-08-28 |
| HRP20251413T1 (hr) | 2025-12-19 |
| MA66951B1 (fr) | 2025-12-31 |
| AU2022369026A1 (en) | 2024-05-02 |
| PT4419510T (pt) | 2026-01-02 |
| SI4419510T1 (sl) | 2026-01-30 |
| MX2024004714A (es) | 2024-05-10 |
| DK4419510T3 (da) | 2025-11-17 |
| PL4419510T3 (pl) | 2026-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021201339B2 (en) | Fenfluramine compositions and methods of preparing the same | |
| US20250250245A1 (en) | Trimetazidine salts | |
| CA3234743C (en) | Novel trimetazidine salts | |
| US20230144283A1 (en) | 8-substituted diaryl xanthines as dual a2a-a2b antagonists | |
| HK40115749B (en) | Novel trimetazidine salts | |
| HK40115749A (en) | Novel trimetazidine salts | |
| HK40108623A (en) | Novel trimetazidine salts | |
| EA048901B1 (ru) | Новые соли триметазидина | |
| JP2026513056A (ja) | 新規トリメタジジン固相 | |
| KR101761466B1 (ko) | 신규한 테노포비어 디소프록실 캠실레이트, 이의 결정형 및 이의 제조방법 | |
| HK40130959A (en) | Novel trimetazidine solid phases | |
| WO2009155488A2 (en) | Novel oxalate salt and crystal of o-desmethylvenlafaxine | |
| HK40107150A (en) | Fenfluramine compositions and methods of preparing the same | |
| HK40107150B (en) | Fenfluramine compositions and methods of preparing the same | |
| HK40040106B (en) | Fenfluramine compositions and methods of preparing the same | |
| HK40040106A (en) | Fenfluramine compositions and methods of preparing the same | |
| HK1262254B (en) | Fenfluramine compositions and methods of preparing the same | |
| HK1262254A1 (en) | Fenfluramine compositions and methods of preparing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40108623 Country of ref document: HK |